Primary melanomas displayed BRAF-mutant protein expression in 23 of 56 (41%) specimens and, for comparison, in 23 of 45 (51%) patients; 28 of 59 (48%) regional metastases or 13 of 25 (52%) patients had BRAFV600E expression, and the highest proportion of BRAFV600E (P < 0.001) was detected among distant metastases, that is, 24 of 34 (71%) tumors or 12 of 18 (67%) patients. Here, BRAF is linked to melanoma.